Quick Dispatch:
Your glp 1 and iih Association between GLP-1 receptor agonist use and neurosurgical intervention in patients with idiopathic intracranial hypertension and obesity: a propensity-matched, multi-institutional, cohort study orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glp 1 and iih Association between GLP-1 receptor agonist use and neurosurgical intervention in patients with idiopathic intracranial hypertension and obesity: a propensity-matched, multi-institutional, cohort study ships.
Need Help?
Questions about glp 1 and iih Association between GLP-1 receptor agonist use and neurosurgical intervention in patients with idiopathic intracranial hypertension and obesity: a propensity-matched, multi-institutional, cohort study, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp 1 and iih Association between GLP-1 receptor agonist use and neurosurgical intervention in patients with idiopathic intracranial hypertension and obesity: a propensity-matched, multi-institutional, cohort study in your area.
Beyond weight loss: a case study and narrative review of the potential role of glucagon-like peptide-1 receptor agonists for the treatment of idiopathic intracranial hypertension - Paulo
20.29
NeuroOp Guru: Stopping GLP-1 therapy may trigger recurrent papilledema in IIH cases | Ophthalmology Times
29.03
The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic intracranial hypertension patients: a retrospective study
25.70
Recurrent Idiopathic Intracranial Hypertension–Related Papilledema After Abrupt Discontinuation of Semaglutide: JNO Article: https://bit.ly/JNO_recurr_IIH_GLP1RA #brain #eye #vision #research #Neurology #NeuroOphth #Ophthalmology #Medicine #Papilledema
23.55
Journal club: GLP-1 receptor agonists in idiopathic intracranial hypertension
21.37
Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension
28.55
A retrospective cohort study assessed outcomes among patients with idiopathic intracranial hypertension who received glucagon-like peptide-1 receptor agonists
24.69
